AR109680A1 - Proteínas recombinantes y sus usos - Google Patents
Proteínas recombinantes y sus usosInfo
- Publication number
- AR109680A1 AR109680A1 ARP170102593A ARP170102593A AR109680A1 AR 109680 A1 AR109680 A1 AR 109680A1 AR P170102593 A ARP170102593 A AR P170102593A AR P170102593 A ARP170102593 A AR P170102593A AR 109680 A1 AR109680 A1 AR 109680A1
- Authority
- AR
- Argentina
- Prior art keywords
- recombinant binding
- amino acid
- acid sequence
- nucleic acids
- binding protein
- Prior art date
Links
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract 6
- 108091008324 binding proteins Proteins 0.000 abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000007562 Serum Albumin Human genes 0.000 abstract 1
- 108010071390 Serum Albumin Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16190221 | 2016-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109680A1 true AR109680A1 (es) | 2019-01-09 |
Family
ID=57046984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102593A AR109680A1 (es) | 2016-09-22 | 2017-09-20 | Proteínas recombinantes y sus usos |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10717772B2 (enExample) |
| EP (1) | EP3515933B9 (enExample) |
| JP (1) | JP6976335B2 (enExample) |
| KR (1) | KR102270315B1 (enExample) |
| CN (1) | CN109790206A (enExample) |
| AR (1) | AR109680A1 (enExample) |
| AU (1) | AU2017331329B2 (enExample) |
| BR (1) | BR112019005587A2 (enExample) |
| CA (1) | CA3036301C (enExample) |
| CL (1) | CL2019000729A1 (enExample) |
| CO (1) | CO2019002609A2 (enExample) |
| ES (1) | ES2953516T3 (enExample) |
| IL (1) | IL265489B (enExample) |
| MX (1) | MX377424B (enExample) |
| MY (1) | MY196882A (enExample) |
| NZ (1) | NZ751689A (enExample) |
| PH (1) | PH12019500596B1 (enExample) |
| SA (1) | SA519401369B1 (enExample) |
| WO (1) | WO2018054971A1 (enExample) |
| ZA (1) | ZA201901592B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3980452A1 (en) * | 2019-06-04 | 2022-04-13 | Molecular Partners AG | Recombinant 4-1bb binding proteins and their use |
| CA3139164A1 (en) * | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Recombinant fap binding proteins and their use |
| KR20220016944A (ko) | 2019-06-04 | 2022-02-10 | 몰리큘라 파트너스 아게 | 개선된 안정성을 갖는 설계된 안키린 반복 도메인 |
| JP2022535564A (ja) * | 2019-06-04 | 2022-08-09 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 多選択性タンパク質 |
| AU2020402581A1 (en) | 2019-12-11 | 2022-06-23 | Molecular Partners Ag | Designed ankyrin repeat domains with altered surface residues |
| MX2022013945A (es) | 2020-05-06 | 2023-02-14 | Molecular Partners Ag | Nuevas proteinas de union a repeticiones de anquirina y sus usos. |
| IL298168A (en) | 2020-05-14 | 2023-01-01 | Molecular Partners Ag | Multispecific proteins |
| AU2021271131A1 (en) * | 2020-05-14 | 2022-12-15 | Molecular Partners Ag | Recombinant CD40 binding proteins and their use |
| US20240108746A1 (en) | 2020-12-16 | 2024-04-04 | Molecular Partners Ag | Novel slow-release prodrugs |
| US20240317852A1 (en) | 2021-03-09 | 2024-09-26 | Molecular Partners Ag | Novel darpin based cd33 engagers |
| WO2022190016A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based multi-specific t-cell engagers |
| CA3211368A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| EP4305063A1 (en) | 2021-03-09 | 2024-01-17 | Molecular Partners AG | Protease cleavable prodrugs |
| WO2023110983A1 (en) | 2021-12-14 | 2023-06-22 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
| CA3262553A1 (en) | 2022-08-01 | 2024-02-08 | Molecular Partners Ag | REHEARSAL AREAS DESIGNED WITH MODIFIED CHARGES AND THEIR USE |
| WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
| IL322519A (en) | 2023-02-17 | 2025-10-01 | Ablynx Nv | Polypeptides that bind to the neonatal fc receptor |
| EP4673159A1 (en) | 2023-02-27 | 2026-01-07 | Molecular Partners AG | Darpins for use in reducing renal accumulation of drugs |
| JP2026524079A (ja) | 2023-06-06 | 2026-07-17 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 組換えｃｄ２結合タンパク質及びその使用 |
| WO2024251628A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd16a binding proteins and their use |
| WO2025146491A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent |
| CN122438868A (zh) | 2024-01-05 | 2026-07-21 | 分子合作伙伴股份公司 | 多特异性结合蛋白 |
| WO2025163144A1 (en) | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Recombinant mesothelin binding proteins and their use |
| WO2025163082A1 (en) * | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Dll3-specific binding constructs and their use in radiotherapy |
| WO2025181039A1 (en) | 2024-03-01 | 2025-09-04 | Molecular Partners Ag | Therapeutic combinations comprising a multi-specific t cell engager |
| WO2026013280A1 (en) * | 2024-07-11 | 2026-01-15 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Designed ankyrin repeat proteins binding p53, and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| EP2518142B1 (en) * | 2001-08-24 | 2015-07-15 | UVic Industry Partnerships Inc. | Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer |
| KR20070085314A (ko) | 2004-11-12 | 2007-08-27 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 재조합 뉴캐슬 질환 바이러스 |
| KR101268939B1 (ko) | 2005-07-08 | 2013-05-30 | 유니버시티 오브 취리히 | 융합 폴리펩티드의 공번역 전좌를 사용한 파아지디스플레이 |
| CA2700391A1 (en) | 2007-09-24 | 2009-04-02 | University Of Zuerich | Designed armadillo repeat proteins |
| CA2706425A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| NZ592591A (en) | 2008-11-03 | 2012-04-27 | Molecular Partners Ag | Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| EP3514169B1 (en) | 2010-11-26 | 2024-03-06 | Molecular Partners AG | Designed repeat proteins binding to serum albumin |
| WO2012149439A2 (en) | 2011-04-29 | 2012-11-01 | Janssen Biotech, Inc. | Il4/il13 binding repeat proteins and uses |
| SG11201408196RA (en) | 2012-06-28 | 2015-03-30 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| EP2906591A1 (en) * | 2012-10-15 | 2015-08-19 | Universität Zürich | Bispecific her2 ligands for cancer therapy |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| US11453708B2 (en) | 2013-05-31 | 2022-09-27 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
| US9458211B1 (en) * | 2015-04-02 | 2016-10-04 | Molecular Partners Ag | Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains |
-
2017
- 2017-09-20 MY MYPI2019001523A patent/MY196882A/en unknown
- 2017-09-20 PH PH1/2019/500596A patent/PH12019500596B1/en unknown
- 2017-09-20 US US15/710,001 patent/US10717772B2/en active Active
- 2017-09-20 EP EP17778226.5A patent/EP3515933B9/en active Active
- 2017-09-20 CN CN201780058511.0A patent/CN109790206A/zh active Pending
- 2017-09-20 MX MX2019003298A patent/MX377424B/es active IP Right Grant
- 2017-09-20 AU AU2017331329A patent/AU2017331329B2/en not_active Ceased
- 2017-09-20 AR ARP170102593A patent/AR109680A1/es not_active Application Discontinuation
- 2017-09-20 NZ NZ751689A patent/NZ751689A/en not_active IP Right Cessation
- 2017-09-20 CA CA3036301A patent/CA3036301C/en active Active
- 2017-09-20 BR BR112019005587A patent/BR112019005587A2/pt not_active Application Discontinuation
- 2017-09-20 ES ES17778226T patent/ES2953516T3/es active Active
- 2017-09-20 KR KR1020197009396A patent/KR102270315B1/ko not_active Expired - Fee Related
- 2017-09-20 WO PCT/EP2017/073768 patent/WO2018054971A1/en not_active Ceased
- 2017-09-20 JP JP2019536693A patent/JP6976335B2/ja not_active Expired - Fee Related
-
2019
- 2019-03-14 ZA ZA2019/01592A patent/ZA201901592B/en unknown
- 2019-03-19 IL IL265489A patent/IL265489B/en unknown
- 2019-03-20 SA SA519401369A patent/SA519401369B1/ar unknown
- 2019-03-21 CO CONC2019/0002609A patent/CO2019002609A2/es unknown
- 2019-03-21 CL CL2019000729A patent/CL2019000729A1/es unknown
-
2020
- 2020-06-22 US US16/907,415 patent/US20210130420A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019002609A2 (es) | Proteínas de unión recombinantes y sus usos | |
| AU2016240220B2 (en) | Designed ankyrin repeat domains with binding specificity for serum albumin | |
| BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
| CL2019003404A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico.(divisional solicitud 201702407) | |
| MX389878B (es) | Proteinas quimericas de factor viii y usos de estas. | |
| CR20220618A (es) | Nuevas proteinas de unión a repeticiones de anquirina y sus usos | |
| ES2531290T3 (es) | Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas | |
| PH12022552935A1 (en) | Stabilized coronavirus spike protein fusion proteins | |
| MX360211B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| ZA202403355B (en) | Single domain antibodies binding to tetanus neurotoxin | |
| PE20170941A1 (es) | Genes de tolerancia a herbicidas y metodos para usar los mismos | |
| AR103586A1 (es) | Proteínas quiméricas que mejoran la actividad de los dominios de unión a adn y factores de transcripción en plantas | |
| EP4286416A4 (en) | Carrier for functional nucleic acid and protein introduction | |
| MX2018002616A (es) | Proteina de fusion. | |
| BR112017000710A2 (pt) | polipeptídeo isolado, polipeptídeo modificado de revestimento final isolado, composição de matéria, polipeptídeo de fusão isolado, composição farmacêutica, método de tratamento de uma doença inflamatória, uso do polipeptídeo isolado, polinucleotídeo isolado, estrutura de ácido nucleico, e método de determinação da potência de um lote do polipeptídeo isolado | |
| AR104390A1 (es) | Polipéptidos dirigidos a la fusión de vih | |
| AR110104A1 (es) | Secuencias potenciadoras de la expresión de proteína y su uso | |
| AR104231A1 (es) | Proteínas de fusión inmunogénicas para el tratamiento del cáncer | |
| AR101293A1 (es) | Célula hospedadora mejorada para producir proteínas | |
| TH177455A (th) | "ระบบการแสดงออกโปรตีนเป้าหมายที่ผิวเซลล์ของยีสต์" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |